Facing Counterfeit Medications in Sexual Medicine. A Systematic Scoping Review on Social Strategies and Technological Solutions
Open Access
- 4 October 2021
- journal article
- review article
- Published by Oxford University Press (OUP) in Sexual Medicine
- Vol. 9 (6) , 100437
Abstract
Introduction: The counterfeit phenomenon is a largely under-reported issue, with potentially large burden for healthcare. The market for counterfeit drugs used in sexual medicine, most notably type 5 phosphodiesterase inhibitors (PDE5i), is rapidly growing.Aims: To report the health risks associated with the use of counterfeit medications, the reasons driving their use, and the strategies enacted to contain this phenomenon.Methods: A systematic scoping review of the literature regarding counterfeit PDE5i was carried between January and June 2021, then updated in August 2021.Main Outcome Measure: We primarily aimed to clarify the main drivers for counterfeit PDE5i use, the health risks associated, and the currently available strategies to fight counterfeiters.Results: One hundred thirty-one records were considered for the present scoping review. Production of fake PDE5i is highly lucrative and the lacking awareness of the potential health risks makes it a largely exploitable market by counterfeiters. Adulteration with other drugs, microbial contamination and unreliable dosages make counterfeit medications a cause of worry also outside of the sexual medicine scope. Several laboratory techniques have been devised to identify and quantify the presence of other compounds in counterfeit medications. Strategies aimed at improving awareness, providing antitampering packaging and producing non-falsifiable products, such as the orodispersible formulations, are also described.Clinical implications: Improving our understanding of the PDE5i counterfeit phenomenon can be helpful to promote awareness of this issue and to improve patient care.Strengths & Limitations: Despite the systematic approach, few clinical studies were retrieved, and data concerning the prevalence of counterfeit PDE5i use is not available on a global scale.Conclusion: The counterfeit phenomenon is a steadily growing issue, with PDE5i being the most counterfeited medication with potentially large harmful effects on unaware consumers.Keywords
This publication has 171 references indexed in Scilit:
- Fingerprinting of sildenafil citrate and tadalafil tablets in pharmaceutical formulations via X-ray fluorescence (XRF) spectrometryJournal of Pharmaceutical and Biomedical Analysis, 2012
- Poor quality vital anti-malarials in Africa - an urgent neglected public health priorityMalaria Journal, 2011
- Detection of counterfeit Viagra® by Raman microspectroscopy imaging and multivariate analysisJournal of Pharmaceutical and Biomedical Analysis, 2011
- A Feasibility Study Comparing Pharmacist and Physician Recommendations for Sildenafil TreatmentThe Journal of Sexual Medicine, 2011
- Economic analysis of use of counterfeit drugs: health impairment risk of counterfeit phosphodiesterase type 5 inhibitor taken as an exampleEnvironmental Health and Preventive Medicine, 2010
- Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risksInternational Journal Of Clinical Practice, 2010
- Anticounterfeit packaging technologiesJournal of Advanced Pharmaceutical Technology & Research, 2010
- Analysis of illegally manufactured formulations of tadalafil (Cialis®) by 1H NMR, 2D DOSY 1H NMR and Raman spectroscopyJournal of Pharmaceutical and Biomedical Analysis, 2008
- Detection of counterfeit Viagra® with Raman spectroscopyJournal of Pharmaceutical and Biomedical Analysis, 2008
- Bitter pillsBMJ, 2007